Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Common Equity (2016 - 2025)

Cardiff Oncology's Common Equity history spans 15 years, with the latest figure at $45.4 million for Q4 2025.

  • For Q4 2025, Common Equity fell 45.28% year-over-year to $45.4 million; the TTM value through Dec 2025 reached $45.4 million, down 45.28%, while the annual FY2025 figure was $45.4 million, 45.28% down from the prior year.
  • Common Equity for Q4 2025 was $45.4 million at Cardiff Oncology, down from $48.8 million in the prior quarter.
  • Across five years, Common Equity topped out at $140.4 million in Q4 2021 and bottomed at $45.4 million in Q4 2025.
  • The 5-year median for Common Equity is $84.8 million (2023), against an average of $90.4 million.
  • The largest annual shift saw Common Equity skyrocketed 1932.52% in 2021 before it plummeted 45.28% in 2025.
  • A 5-year view of Common Equity shows it stood at $140.4 million in 2021, then dropped by 24.27% to $106.3 million in 2022, then plummeted by 34.42% to $69.7 million in 2023, then rose by 18.94% to $82.9 million in 2024, then tumbled by 45.28% to $45.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Common Equity are $45.4 million (Q4 2025), $48.8 million (Q3 2025), and $58.6 million (Q2 2025).